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sores, and diabetic foot ulcers, are challenging medical
issues that physicians are increasingly facing. With the
growing incidence of this problem, a great amount of
research into possible treatments, such as topical applica-
tion of growth factors, has been funded with the goal of
helping augment the healing of chronic wounds; but these
treatments have provided unsatisfactory outcomes in clin-
ical trials. Insufficient inflammation, cellular proliferation,
and migration, as well as extracellular matrix (ECM) depo-
sition and angiogenesis are common to all complex tissue
defects.
Numerous studies have indicated that bone-marrow-
derived stem cells may contribute to tissue repair or
regeneration,1,2 which provides us with a new perspective
in wound healing. In the early 1990s, a distinct population
of fibroblast-like cells was discovered by their rapid and
specific recruitment from the circulation to implanted
wound chambers in mice.3 These cells, which are now
called fibrocytes, comprise 0.1e0.5% of nonerythrocytic
cells in the peripheral blood.3 Fibrocytes are bone marrow-
derived cells that appear to differentiate from the circu-
lating CD14þ cell population and exhibit hematopoietic
stem cell and stromal cell characteristics. It has been
revealed that fibrocytes can migrate to wound sites via
several chemokine receptors, including chemokine
receptor 3 (CCR3), CCR5, CCR7, and C-X-C chemokine* Corresponding author. The Third Xiangya Hospital of Central
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doi:10.1016/j.jfma.2011.05.003receptor type 4.4 Fibrocytes appear to be precursor stem
cells of myofibroblasts, which are essential in wound
contraction and healing. Dermal regeneration during wound
healing may depend on the recruitment of fibrocytes.
Fibrocytes are able to enter wound sites and participate
in local inflammatory and wound-healing responses. Fibro-
cytes purified from wound chambers were found to secrete
inflammatory cytokines including interleukin (IL)-1b, IL-10,
and tumor necrosis factor (TNF)-a.5 IL-1b and TNF-a, two
important mediators of the wound-healing response, can
stimulate chemokine and hemopoietic growth factor
secretion in vitro. Compared with the coexistent mono-
cytes and T cells isolated from the wound chamber, fibro-
cytes expressed a higher level of macrophage inflammatory
protein (MIP)-1, 2, platelet-derived growth factor (PDGF),
transforming growth factor (TGF)-b, and macrophage
colony stimulating factor (M-CSF).5 These cytokines and
growth factors play an essential role in inflammatory
response, cellular proliferation and migration, ECM depo-
sition, and angiogenesis during wound healing.
Wounds or tissue injuries result in a loss of integrity of
the skin. Damage to this critical immune defense barrier
allows pathogenic bacteria to invade and infection to
occur. Chesney et al revealed that fibrocytes were involved
in the initiation of immunity to defend the body during
tissue injury and repair. Fibrocytes can initiate antigen-
specific immunity through antigen-presenting cells (APCs)
and have a proliferative activity between monocytes (low)
and dendritic cells (high) in vitro.6 Furthermore, human
fibrocytes secrete MIP-1a and MIP-1b, which are potent
chemoattractant molecules for CD4 þ T cells. These CD4 þ
T cells, which are essential for the generation of antigen-& Formosan Medical Association. All rights reserved.
2 C. Peng et al.specific responses in vivo, are major immunoregulators in
wound healing. Thus, fibrocytes contribute to wound
healing by regulating the host defense response during
tissue injury.
The ECM contributes to wound healing by regulating cell
proliferation, survival, shape, migration, and differentia-
tion. Ex-vivo cultured fibrocytes express numerous ECM
molecules, including vimentin, fibronectin, collagen I, and
collagen III,3 demonstrating the ability to produce ECM
proteins. Moreover, treatment of ex-vivo cultured fibro-
cytes isolated from peripheral blood with TGF-b enhanced
both collagen production and a-SMA (smooth muscle actin)
expression by these cells. Fibrocytes can differentiate into
mature myofibroblasts7 and serve as a contractile force via
a-SMA expression in response to TGF-b.4 Myofibroblasts are
known to exert a critical contractile force to pull the wound
edges together. In addition, these cells exhibit increased
levels of a-SMA, enhanced collagen production, and other
ECM proteins that accelerate wound contracture and
healing in response to TGF-b in vitro. Therefore, fibrocytes
can facilitate wound closure by producing ECM proteins and
accelerating wound contracture in the presence of TGF-b.
It has also been revealed that fibrocytes play a critical
role in angiogenesis.8,9 Angiogenesis is a key phase in
wound closure, which includes proteolytic degradation of
the matrix as well as migration, proliferation, and tube
formation by vascular endothelial cells. Ex-vivo cultured
fibrocytes secrete high levels of active matrix metal-
loproteinase 9,9 which can mediate the dissolution of the
basement membrane during early tissue repair and initiate
endothelial cell invasion, and may further facilitate
angiogenesis. Fibrocytes promote endothelial cell prolifer-
ation by producing several proangiogenic factors, including
vascular endothelial growth factor, PDGF, IL-8, IL-1b, M-
CSF, hepatocyte growth factor, granulocyte-macrophage-
CSF, basic fibroblast growth factor, and connective tissue
growth factor.9 In addition to the role of fibrocytes in
accelerating endothelial cell proliferation in vivo, culture
supernatants from fibrocytes were found to have the ability
to promote endothelial cell migration and differentiation
(tube formation) in vitro.9 Moreover, an in-vivo Matrigel
implant model of angiogenesis demonstrated that fibro-
cytes and fibrocyte culture supernatants promoted blood
vessel formation.9 Thus, fibrocytes are postulated to have
an important role in blood vessel formation during woundhealing due to their ability to promote endothelial cell
proliferation, migration, and differentiation in vivo.
In summary, fibrocytes play an essential role in wound
healing by initiating antigen-specific immunity as APCs;
secreting cytokines, growth factors, and ECM proteins;
accelerating wound contraction; and promoting angiogen-
esis. Fibrocytes participate in the phases of wound healing
and demonstrate the ability to accelerate wound healing.
Furthermore, fibrocytes can easily be obtained through
peripheral blood and can further be propagated into
a larger numbers with high purity ex vivo before being
applied back into wounds. Therefore, it is reasonable to
believe that fibrocytes can hopefully provide us with
a promising therapeutic strategy for chronic wounds.References
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